Literature DB >> 12105315

Preference-based quality-of-life in patients with Parkinson's disease.

Andrew Siderowf1, Bernard Ravina, Henry A Glick.   

Abstract

BACKGROUND: Preference-based instruments are a specific type of health-related quality-of-life scale designed to measure the relative value of health. Because of this property, they are the appropriate measures of quality of life for cost-effectiveness analysis. Although preference-based scales are widely used, their validity has rarely been tested in specific patient groups.
OBJECTIVES: To assess quality of life using preference-based scales in a group of patients with PD and to compare these scores with measures of clinical severity and traditional quality of life.
METHODS: Each patient was rated using the Disability and Distress Index (DDI), the Euroqol System (EQ-5D), and the Health Utilities Index Mark II (HUI). Clinical severity was measured using the Unified PD Rating Scale (UPDRS) and PD Questionnaire-39 (PDQ-39) quality-of-life instrument. Results from preference-based instruments were compared with each other and with clinical measures of disease severity.
RESULTS: One hundred subjects participated in the study, and 97 completed all preference-based instruments. Scores from all three instruments correlated well with the UPDRS and most domains of the PDQ-39. The mean scores for the DDI, HUI, and EQ-5D were 0.92 (range 0 to 1), 0.74 (range 0.19 to 1), and 0.58 (range -0.429 to 1). Differences between mean scores for the instruments were significant.
CONCLUSIONS: In the sample of patients with PD, the Disability and Distress Index, Euroqol System, and the Health Utilities Index Mark II correlate well with measures of disease severity and quality of life. However, they give strikingly different values. When applied in cost-effectiveness analysis, these discrepancies could result in substantially different cost-effectiveness ratios for PD-related interventions.

Entities:  

Mesh:

Year:  2002        PMID: 12105315     DOI: 10.1212/wnl.59.1.103

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  22 in total

1.  Sentence processing in Lewy body spectrum disorder: the role of working memory.

Authors:  Rachel G Gross; Corey T McMillan; Keerthi Chandrasekaran; Michael Dreyfuss; Sharon Ash; Brian Avants; Philip Cook; Peachie Moore; David J Libon; Andrew Siderowf; Murray Grossman
Journal:  Brain Cogn       Date:  2012-01-02       Impact factor: 2.310

2.  Pramipexole and levodopa in early Parkinson's disease: dynamic changes in cost effectiveness.

Authors:  Katia Noyes; Andrew W Dick; Robert G Holloway
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

3.  Relationship among sociodemographic factors, clinical conditions, and health-related quality of life: examining the EQ-5D in the U.S. general population.

Authors:  Erica I Lubetkin; Haomiao Jia; Peter Franks; Marthe R Gold
Journal:  Qual Life Res       Date:  2005-12       Impact factor: 4.147

4.  The impact of motor and non motor symptoms on health state values in newly diagnosed idiopathic Parkinson's disease.

Authors:  James Shearer; Colin Green; Carl E Counsell; John P Zajicek
Journal:  J Neurol       Date:  2011-08-05       Impact factor: 4.849

Review 5.  The Promise of Telemedicine for Movement Disorders: an Interdisciplinary Approach.

Authors:  H Ben-Pazi; P Browne; P Chan; E Cubo; M Guttman; A Hassan; J Hatcher-Martin; Z Mari; E Moukheiber; N U Okubadejo; A Shalash
Journal:  Curr Neurol Neurosci Rep       Date:  2018-04-13       Impact factor: 5.081

6.  Mapping the eight-item Parkinson's Disease Questionnaire (PDQ-8) to the EQ-5D utility index.

Authors:  Y B Cheung; L C S Tan; P N Lau; W L Au; N Luo
Journal:  Qual Life Res       Date:  2008-09-20       Impact factor: 4.147

Review 7.  Cost effectiveness of pharmacotherapies in early Parkinson's disease.

Authors:  Karla M Eggert; Jens P Reese; Wolfgang H Oertel; Richard Dodel
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

8.  The classification systems of the EQ-5D, the HUI II and the SF-6D: what do they have in common?

Authors:  Uwe Konerding; Jörn Moock; Thomas Kohlmann
Journal:  Qual Life Res       Date:  2009-09-01       Impact factor: 4.147

9.  Health state values during the first year of drug treatment in early-stage Parkinson's disease: a prospective, population-based, cohort study.

Authors:  Corinna Vossius; Odd Bjarte Nilsen; Jan Petter Larsen
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

10.  Bayesian multiple imputation for missing multivariate longitudinal data from a Parkinson's disease clinical trial.

Authors:  Sheng Luo; Andrew B Lawson; Bo He; Jordan J Elm; Barbara C Tilley
Journal:  Stat Methods Med Res       Date:  2012-12-12       Impact factor: 3.021

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.